Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Aligos TherapeuticsUpdated: May 1, 2026Locations: 58
Eligibility criteria

Male or female between 18 and 65 years of age, with body mass index (BMI) of 18.... [+6]

Co-infection with hepatitis A, C, D, E or HIV or any evidence of clinically sign... [+9]

Read more
Status: Recruiting

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Aligos TherapeuticsUpdated: Feb 27, 2026Locations: 2
Eligibility criteria

Male and Female between 18 and 75 years old [+9]

Subjects with any current or previous illness that, in the opinion of the Invest... [+11]

Read more
Status: Recruiting

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).

Participants needed: 16
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Aligos TherapeuticsUpdated: Feb 4, 2026Locations: 1
Eligibility criteria

Male and Female between 18 and 75 years old [+10]

Subjects with any current or previous illness that, in the opinion of the Invest... [+19]

Read more